Subscribe to NRx Newsletter

NRXP

Aug. 16, 2021
NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure Emergency Use Authorization Granted to ZYESAMI in Nation of Georgia to Treat Critical COVID-19 Patients in July; First Orders for ZYESAMI in Georgia Under Discussion NRx Pharmaceuticals Initiating Phase […]

Read More
Dec. 14, 2020
BIG ROCK PARTNERS ACQUISITION CORP. ANNOUNCES MERGER WITH NEURORX, INC.

Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of COVID-19 (RLF-100 or “ZYESAMI™ (aviptadil)”) and Bipolar Depression (NRX-100, […]

Read More